Vaccine Therapy in Treating Patients Who Have Undergone Autologous Stem Cell Transplant for High-Risk Lymphoma or Multiple Myeloma

DISEASE CHARACTERISTICS:

• Diagnosis of multiple myeloma OR any of the following high-risk lymphomas:

  • Diffuse large B-cell lymphoma meeting any of the following criteria:

    • Failed induction therapy but responded to salvage therapy
    • Relapsed < 1 year after completion of induction therapy
    • Elevated lactic dehydrogenase (LDH) at relapse
    • Stage III or IV disease at relapse
    • Positive PET scan after induction or salvage therapy
    • Age 60 to 75 years

  • Follicular lymphoma meeting any of the following criteria:

    • Progressive disease after two or more prior regimens
    • Transformed to aggressive diffuse large B-cell lymphoma but is still chemotherapy sensitive
    • Not considered to be a good candidate for allogeneic stem cell transplantation

  • Hodgkin lymphoma meeting any of the following criteria:

    • Primary refractory disease
    • Relapsed < 1 year after completion of induction therapy
    • Relapsed with PET positive disease after salvage therapy
    • Relapsed refractory disease and is not considered to be a good candidate for allogeneic stem cell transplantation

  • Mantle cell lymphoma meeting any of the following criteria:

    • Chemotherapy sensitive disease after induction therapy
    • Chemotherapy sensitive relapsed disease and is not considered to be a good candidate for allogeneic stem cell transplantation

  • T-cell non-Hodgkin lymphoma (NHL) meeting any of the following criteria:

    • Peripheral T-cell lymphoma, not otherwise specified meeting at least one of the following criteria:

      • High LDH at diagnosis
      • Marrow involvement at diagnosis
      • Age > 60 years at diagnosis
      • Low platelet count at diagnosis
      • Chemotherapy sensitive relapsed disease
    • Angioimmunoblastic lymphadenopathy with dysproteinemia
    • ALK-negative anaplastic NHL
    • Enteropathy-associated T-cell NHL
    • Stage III or IV NK-/T-cell NHL at diagnosis
    • NK-blastic NHL
• Has undergone autologous hematopoietic stem cell transplantation and received 200 mg/m² of melphalan (for multiple myeloma) OR BEAM chemotherapy comprising carmustine, etoposide, cytarabine, and methotrexate (for high-risk lymphoma) as conditioning therapy

PATIENT CHARACTERISTICS:

• ECOG or WHO performance status 0-2
• ANC ≥ 1,000/μL
• Platelet count ≥ 75,000/μL
• Total bilirubin ≤ 1.5 mg/dL
• Alkaline phosphatase ≤ 2 times upper limit of normal (ULN)
• AST and ALT ≤ 2 times the ULN
• Not pregnant or nursing
• No severe or uncontrolled systemic illness

• No "currently active" second malignancy, other than nonmelanoma skin cancer or carcinoma in situ of the cervix

  • Patients are not considered to have a "currently active" malignancy if they completed therapy for the malignancy, are disease free from the malignancy for > 5 years, and are considered by their physician to be at < 30% risk of relapse

• No significant history of uncontrolled cardiac disease including, but not limited to, any of the following:

  • Uncontrolled hypertension
  • Unstable angina
  • Recent myocardial infarction (within the past 6 months)
  • Uncontrolled congestive heart failure
• No active bacterial, fungal, or viral infection
• No known HIV infection or active hepatitis B and/or hepatitis C infection
• No other medical condition, including mental illness or substance abuse, deemed by the investigator(s) to likely interfere with the patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the study results

PRIOR CONCURRENT THERAPY:

• No concurrent biologic therapy, chemotherapy, or other antineoplastic therapy